These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 16860461)

  • 21. [Hormone therapy of locally advanced cancer of the prostate validated by several randomized trials].
    Mazeron JJ
    Bull Cancer; 2011 Feb; 98(2):93-4. PubMed ID: 21591300
    [No Abstract]   [Full Text] [Related]  

  • 22. Letter to the Editor; Re: Wirth MP, Weissbach L, Marx F-J, Heckl W, Jellinghaus W, Riedmiller H, Noack B, Hinke A, Froehner M. Prospective randomized trial comparing flutamide as adjuvant treatment versus observation after radical prostatectomy for locally advanced, lymph node-negative prostate cancer. Eur Urol 2004;45:267-70.
    Rocco B; Matei DV; de Cobelli O; Rocco F
    Eur Urol; 2004 Aug; 46(2):272-3; author reply 273. PubMed ID: 15245825
    [No Abstract]   [Full Text] [Related]  

  • 23. What should I know about Lupron Depot for treating prostate cancer?
    Johns Hopkins Med Lett Health After 50; 2012 Jan; 23(11):7. PubMed ID: 22396997
    [No Abstract]   [Full Text] [Related]  

  • 24. Twenty-five year evolution of medical hormonal therapy for prostate cancer.
    Moul JW
    BJU Int; 2009 Jan; 103(2):145-6. PubMed ID: 19278531
    [No Abstract]   [Full Text] [Related]  

  • 25. Global update on defining and treating high-risk localized prostate cancer with leuprorelin: an Asian perspective.
    Mizokami A; Ueno S; Fukagai T; Ito K; Ehara H; Kinbara H; Origasa H; Usami M; Namiki M; Akaza H
    BJU Int; 2007 Jan; 99 Suppl 1():6-9; discussion 17-8. PubMed ID: 17229160
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prostate specific antigen (PSA) may be a poor marker for progression of prostate cancer after treatment with a combination of chemo-hormonal therapies.
    Sartor O
    J La State Med Soc; 2008; 160(2):99-100. PubMed ID: 18681353
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Leuprolide: a review of its effects in comparison with diethylstilboestrol in the treatment of advanced cancer of the prostate.
    Garnick MB; Glode LM; Smith JA; Max DT
    Br J Clin Pract Suppl; 1985 Mar; 37():8-12, 20-4. PubMed ID: 3931665
    [No Abstract]   [Full Text] [Related]  

  • 28. Estrogen therapy for prostate carcinoma.
    Presti JC
    JAMA; 1996 Apr; 275(15):1153. PubMed ID: 8609673
    [No Abstract]   [Full Text] [Related]  

  • 29. Undetectable level of prostate specific antigen (PSA) nadir predicts PSA biochemical failure in local prostate cancer with delayed-combined androgen blockade.
    Soga N; Arima K; Sugimura Y
    Jpn J Clin Oncol; 2008 Sep; 38(9):617-22. PubMed ID: 18697759
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Re: Bertrand Tombal, Sean Collins, Alicia K. Morgans, et al. Impact of Relugolix Versus Leuprolide on the Quality of Life of Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study. Eur Urol 2023;84:579-87.
    Rush HL; Gilbert DC; Langley RE
    Eur Urol; 2024 Jun; 85(6):e164-e165. PubMed ID: 38584074
    [No Abstract]   [Full Text] [Related]  

  • 31. Re: Michael J. Morris, Daisy Huang, William K. Kelly, et al. Phase 1 trial of high-dose exogenous testosterone in patients with castration-resistant metastatic prostate. Eur Urol 2009;56:237-44.
    Drewa T; Chlosta P
    Eur Urol; 2010 Feb; 57(2):e18-9; author reply e20. PubMed ID: 19853990
    [No Abstract]   [Full Text] [Related]  

  • 32. Re: Expression of estrogen related proteins in hormone refractory prostate cancer: association with tumor progression. O. Celhay, M. Yacoub, J. Irani, B. Dore, O. Cussenot and G. Fromont. J Urol 2010; 184: 2172-2178.
    Zhang M
    J Urol; 2011 Aug; 186(2):756. PubMed ID: 21683411
    [No Abstract]   [Full Text] [Related]  

  • 33. [A posteriori biological demonstration of the concept of hormone-radiotherapy combination in cancer of the prostate].
    Magné N
    Bull Cancer; 2013 May; 100(5):415-6. PubMed ID: 23862197
    [No Abstract]   [Full Text] [Related]  

  • 34. Leuprolide implant approved for once-yearly palliative treatment of advanced prostate cancer.
    Oncology (Williston Park); 2000 Jun; 14(6):828, 830. PubMed ID: 10887633
    [No Abstract]   [Full Text] [Related]  

  • 35. Combined prostate brachytherapy and short-term androgen deprivation therapy as salvage therapy for locally recurrent prostate cancer after external beam irradiation.
    Wong WW; Buskirk SJ; Schild SE; Prussak KA; Davis BJ
    J Urol; 2006 Nov; 176(5):2020-4. PubMed ID: 17070243
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anaemia following initiation of androgen deprivation therapy for metastatic prostate cancer: a retrospective chart review.
    Curtis KK; Adam TJ; Chen SC; Pruthi RK; Gornet MK
    Aging Male; 2008 Dec; 11(4):157-61. PubMed ID: 18937151
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Re: Hendrik Isbarn, Jehonathan H. Pinthus, Leonard S. Marks, et al. Testosterone and prostate cancer: revisiting old paradigms. Eur Urol 2009;56:48-56.
    Friedman AE
    Eur Urol; 2009 Nov; 56(5):e23; author reply e24. PubMed ID: 19586711
    [No Abstract]   [Full Text] [Related]  

  • 38. Focusing on testosterone.
    Moul JW; Dreicer R
    Urology; 2011 Nov; 78(5 Suppl):S476-7. PubMed ID: 22054917
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Population based study of hormonal therapy and survival in men with metastatic prostate cancer.
    Lu-Yao G; Moore DF; Oleynick JU; DiPaola RS; Yao SL
    J Urol; 2007 Feb; 177(2):535-9. PubMed ID: 17222628
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hormonal therapy for advanced prostate cancer.
    Vaughn DJ
    Ann Intern Med; 2000 Apr; 132(7):584-5. PubMed ID: 10744596
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.